Seat­tle's AGC plots $194M in­vest­ment to dou­ble pro­duc­tion at Copen­hagen site in busy year for bi­o­log­ics

Bi­o­log­ics man­u­fac­tur­ing is an ex­pen­sive and com­pli­cat­ed process — but that hasn’t stopped some of the bio­phar­ma in­dus­try’s biggest play­ers from mak­ing big splash­es in re­cent years. Now, a Seat­tle-based CD­MO is drop­ping a ma­jor down pay­ment to dou­ble its pres­ence in the field.

Cit­ing an in­creased de­mand from glob­al part­ners, Seat­tle-based AGC Bi­o­log­ics will pour $194 mil­lion in­to flesh­ing out its bi­o­log­ics man­u­fac­tur­ing at its Copen­hagen site, the com­pa­ny said late last month. The rough­ly 204,000-square-foot ex­pan­sion in a new build­ing will al­low the glob­al CD­MO to dou­ble its ca­pac­i­ty for work with sin­gle-use biore­ac­tor mam­malian cell-cul­tures.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.